These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 29627023)

  • 1. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
    Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
    Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
    Kmiecik MJ; Micheletti S; Coker D; Heilbron K; Shi J; Stagaman K; Filshtein Sonmez T; Fontanillas P; Shringarpure S; Wetzel M; Rowbotham HM; Cannon P; Shelton JF; Hinds DA; Tung JY; ; Holmes MV; Aslibekyan S; Norcliffe-Kaufmann L
    Brain; 2024 Jun; 147(6):1996-2008. PubMed ID: 38804604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic.
    Ben Romdhan S; Farhat N; Nasri A; Lesage S; Hdiji O; Ben Djebara M; Landoulsi Z; Stevanin G; Brice A; Damak M; Gouider R; Mhiri C
    Acta Neurol Scand; 2018 Nov; 138(5):425-431. PubMed ID: 29989150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
    Alcalay RN; Mejia-Santana H; Tang MX; Rosado L; Verbitsky M; Kisselev S; Ross BM; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Caccappolo E; Ottman R; Clark LN; Marder KS
    Arch Neurol; 2009 Dec; 66(12):1517-22. PubMed ID: 20008657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
    Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
    Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
    Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
    Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
    Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
    J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.